Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 3,077 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Intracranial Vascular Disorders Clear all

Conditions: Ischemic Stroke
Interventions: Vagus nerve stimulation (VNS) paired with mobility training; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Carotid Stenosis, Stroke, Carotid Artery Plaque, Transient Ischemic Attack, Cerebrovascular Accident, Carotid Artery Stenosis
Interventions: Carotid Endarterectomy or Stenting; Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Aneurysm
Interventions: SHIELD; Device
Lead sponsor: Jacobs institute; Other
Eligibility: 22 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cerebral Small Vessel Diseases, Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy, Cerebral Microbleeding, Sporadic White Matter Disease
Interventions: Cilostazol; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: Deferoxamine, Placebo; Drug
Lead sponsor: Aditya S. Pandey, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hemiparesis, Ischemic Stroke, Chronic
Interventions: Robot Therapy Device, Occupational Therapy; Device · Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 30 Years to 85 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Milwaukee, Wisconsin

Conditions: Stroke
Interventions: Hand Mentor (TM) robotic stroke therapy device, Home Therapy Program; Device
Lead sponsor: Kinetic Muscles; Industry
Eligibility: 21 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Atlanta, Georgia • Cleveland, Ohio

Conditions: Intra Cerebral Hemorrhage, ICH - Intracerebral Hemorrhage, ICH, Hemorrhage, Stroke, Clot (Blood); Brain, Clot Blood, Cognitive Decline, Cognitive Impairment, Survivorship, Memory Impairment, Motor Activity
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: Not listed
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 26
States / cities: Birmingham, Alabama • La Jolla, California • Sacramento, California + 21 more

Conditions: Stroke
Interventions: Magnesium Chloride, Placebo; Drug
Lead sponsor: Relox Medical, LLC; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Grand Rapids, Michigan • Suffern, New York • Toledo, Ohio

Conditions: Stroke, Aphasia
Interventions: continuous Theta Burst Stimulation, intermittent Theta Burst Stimulation, Transcranial Magnetic Stimulation Sham, Semantic Feature Analysis; Device · Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Acute Stroke
Interventions: SCM, SCM and VSSP; Other
Lead sponsor: Michigan State University; Other
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Lansing, Michigan • Ypsilanti, Michigan

Conditions: Traumatic Brain Injury
Interventions: 1 gram Tranexamic Acid (TXA), 2 grams TXA, 0.9% Sodium Chloride injectable; Drug
Lead sponsor: University of Washington; Other
Eligibility: 15 Years and older
Enrollment: 967 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 10
States / cities: Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota + 7 more

Conditions: Embolic Stroke of Undetermined Source
Interventions: Not listed
Lead sponsor: Population Health Research Institute; Other
Eligibility: 21 Years to 50 Years
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 7
States / cities: Stanford, California • Joliet, Illinois • Greensboro, North Carolina + 4 more

Conditions: Sialorrhea
Interventions: MYOBLOC; Drug
Lead sponsor: Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 26
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Loma Linda, California + 22 more

Conditions: Alzheimer's Disease
Interventions: No intervention; Other
Lead sponsor: Eisai Inc.; Industry
Eligibility: Not listed
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Nutley, New Jersey

Conditions: Chronic Subdural Hematoma
Interventions: Experimental: Interventional Cohort: TRUFILL n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic System, Standard of Care Surgery, Experimental: Interventional Cohort: TRUFILL n-BCA Liquid Embolic System, Standard of Care Medical Management; Device · Other
Lead sponsor: Cerenovus, Part of DePuy Synthes Products, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 31
States / cities: Birmingham, Alabama • Tucson, Arizona • Walnut Creek, California + 28 more

Conditions: Leukodystrophy, White Matter Disease, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts 1, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication &#X7C; Blood or Tissue &#X7C; Mutations, Pelizaeus-Merzbacher-Like Disease, 1, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 18 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Stroke
Interventions: WalkAide, AFO; Device
Lead sponsor: Innovative Neurotronics; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 5
States / cities: Phoenix, Arizona • San Francisco, California • St Louis, Missouri + 2 more

Conditions: Sturge - Weber Syndrome (SWS)
Interventions: Epidiolex 100 mg/mL Oral Solution; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 1 Month to 18 Months
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stroke
Interventions: CO-OP, Standard Occupational Therapy; Behavioral
Lead sponsor: St. John's Rehab Hospital; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hypoxic-Ischemic Encephalopathy, Neonatal Encephalopathy, Encephalopathy
Interventions: Visual Evoked Potential (VEP), Electroretinogram (ERG); Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Up to 36 Months
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: White Matter Injury, Brain Injury, Fetus and Neonate, Neonatal Brain Injury, Periventricular Leukomalacia, Periventricular White Matter Abnormalities
Interventions: Clemastine fumarate; Drug
Lead sponsor: Bridget LaMonica Ostrem, M.D., Ph.D.; Other
Eligibility: 3 Weeks to 20 Weeks
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stroke, Stroke (CVA) or Transient Ischemic Attack, Stroke Ischemic, Stroke Gait Rehabilitation, Balance Deficits
Interventions: Combined (Robotic balance training and high-definition transcranial direct current stimulation), Standard of Care Balance Training; Device · Other
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Carotid Atherosclerosis
Interventions: Perflutren; Diagnostic Test
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

A Study Of Vagus Nerve Stimulation (VNS) With Mobility Training For Gait Recovery After Chronic Ischemic Stroke

Structural Stability of Carotid Plaque and Symptomatology

Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm (SHIELD)

Retina is a Marker for Cerebrovascular Heath

Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)

Functional Magnetic Resonance Imaging (fMRI) and Robot-Assisted Practice of Activities of Daily Living

Rehabilitation of the Stroke Hand at Home

REpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study

Magnesium Chloride Versus Placebo in Patients Who Have Had a Stroke

Recovery From Post-Stroke Aphasia With rTMS Targeting Left or Right Anterior Temporal Lobe

Michigan Stroke Transitions Trial

Prehospital Tranexamic Acid Use for Traumatic Brain Injury

Young ESUS Patient Registry

Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults

A Retrospective Database Study for the Development and Validation of Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's Disease

Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA

LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies

Efficacy of the WalkAide and AFOs for CVA

Epidiolex Trial for Presymptomatic Treatment of Sturge-Weber Syndrome

Exploring the Efficacy of Combined Task-Specific and Cognitive Strategy Training in Subacute Stroke

Healthy Little Eyes

Neonatal White Matter Injury Trial (WRAP)

Neuromodulation-Enhanced Use of RObotic BALANCE Training to Improve Balance Function in Individuals With Stroke

Risk Assessment of Carotid Plaques Using 3D Contrast-Enhanced Ultrasound